Health Current

Belkins
Arizona Health-e Connection Is Now Health Current Powering the future of healthcare with more complete information. Health Current is the health information exchange (HIE) that helps partners transform care by bringing together communities and information across Arizona. More complete information is more meaningful and leads to better care and better outcomes. It makes healthcare transformation possible. That’s why we’ve worked for more than ten years to become Arizona’s primary resource for information technology and exchange, integrating information with the delivery of care to improve the health and wellbeing of individuals and communities. As we’ve grown, our core goal has remained the same: help providers use information technology to improve people’s lives.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

EXACT SCIENCES ACQUIRES PREVENTIONGENETICS TO ACCELERATE AVAILABILITY OF HEREDITARY CANCER TESTING FOR MORE PATIENTS

Exact Sciences Corporation | January 10, 2022

news image

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

Read More

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

news image

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...

Read More

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

news image

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

news image

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More
news image

CELL AND GENE THERAPY

EXACT SCIENCES ACQUIRES PREVENTIONGENETICS TO ACCELERATE AVAILABILITY OF HEREDITARY CANCER TESTING FOR MORE PATIENTS

Exact Sciences Corporation | January 10, 2022

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

Read More
news image

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...

Read More
news image

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More
news image

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us